Tagged: drug Toggle Comment Threads | Keyboard Shortcuts

  • Anouk Lorie 12:22 pm on June 24, 2014 Permalink | Reply
    Tags: , drug, , neurim pharma, pharamceuticals   

    Neurim Pharma Reports Successful Trial Of Circadin On Alzheimer’s Patients 

    neurimJune 24, 2014 | Israeli pharmaceutical company Neurim Pharmaceuticals reported the completion of an initial efficiency trial of its drug Circadin for the treatment of Alzheimer’s disease, together with existing treatments of the disease. Circadin is currently sold as drug for the treatment of sleeping disorders, based on the delayed release of melatonin. Because melatonin levels are low in the early stages of Alzheimer’s disease, the company decided it would be worthwhile to see if Circadin could help Alzheimer’s patients control the effect of some of the symptoms together with standard methods of treatment. Neurim Pharma was founded by CTO Prof. Nava Zisapel, with the main investors of the company being Nava herself and Yehuda Zisapel. Today, Circadin is sold in over 40 countries for the treatment of sleep disorders.

  • NoCamels Team 2:25 pm on November 7, 2012 Permalink | Reply
    Tags: , drug, , lung disease   

    Pharmaceutical Company Kamada Discovers Diabetes Drug Efficient For Lung Disease 

    Pharmaceutical Company Kamada Discovers Diabetes Drug Efficient For Lung DiseaseIsraeli drug company Kamada reports that on recent clinical trials done with its Glassia drug, results have shown positive results for treating lung disease. Laboratory mice with bacterial lung infection have shown significant improvement once treated with the drug.

  • NoCamels Team 12:10 pm on October 15, 2012 Permalink | Reply
    Tags: drug, emphysema, ,   

    Kamada Receives FDA Approval For Emphysema Study 

    Kamada Receives FDA Approval For Emphysema StudyIsraeli pharmaceutical company Kamada has announced that it has received FDA approval for a phase II and III clinical trial of AATD-IH, an inhalable version of its AAT drug, which is designed to treat congenital emphysema.

  • NoCamels Team 8:28 am on June 24, 2012 Permalink | Reply
    Tags: drug, , , , ,   

    ‘Perrigo’ To Invest $40M To Expand Israeli Plants 

    Perrigo - News Flash - IsraelPerrigo, the US generic drug company, announced it will invest $40 million over the next three years, in order to expand its R&D and production in its two plants in Israel. As part of the investment, Perrigo says it plans to add 100 employees to its  plants in Yeruham and Ramat Hovav in the Israeli Negev. The company currently employs approximately 7,000 employees worldwide, out of them 900 in Israel.

  • NoCamels Team 1:22 pm on June 18, 2012 Permalink | Reply
    Tags: , drug, , , ,   

    Cancer Therapy Developer KAHR Medical To Raise $2.6M 

    KAHR - News Flash - IsraelKAHR Medical, the developer of novel drugs for the treatment of cancer and autoimmune diseases, will raise $2.6 million at a pre-investment valuation of $11 million. KAHR Medical is a portfolio company in which Hadasit Bio-Holdings, a publicly traded portfolio of biotech companies based on intellectual property developed by the Hadassah University Hospital, and Sanofi hold approximately 70% and 20% respectively. Thomas Eldered, co-owner of Recipharm, will invest $2 million and hold approximately 15% of the company. The pharmaceutical company Sanofi will maintain its current holdings with an investment of $500,000. Hadasit Bio-Holdings will invest an additional $100,000 and reduce its holding in the company to approximately 55%.

  • NoCamels Team 7:58 am on May 30, 2012 Permalink | Reply
    Tags: , drug, IntelGenx, , , RHB-103   

    ‘RedHill’ Announces Successful Clinical Trial Of Migraine Treatment 

    RedHill Logo - News Flash - IsraelRedHill Biopharma, an Israeli biopharmaceutical company announced positive results in a clinical trial with RHB-103, an oral thin-film formulation of Rizatriptan for the treatment of acute migraine. According to the company, the trial, which was conducted in Canada, met its specified endpoints and FDA’s criteria. RedHill focuses primarily on development of late clinical-stage, patent protected, new formulations and combinations of existing drugs. It is developing RHB-103 with its Canadian co-development partner IntelGenx. The company is targeting a segment of the migraine market – namely the family of triptan migraine drugs – estimated at approximately $2 billion in 2011.

  • NoCamels Team 7:18 am on May 2, 2012 Permalink | Reply
    Tags: drug, FDA Approval, Gaucher Disease,   

    ‘Protalix’ Gets FDA Approval Of Gaucher Disease Drug 

    Protalix - News Flash - IsraelThe U.S. Food and Drug Administration’s approved for marketing Protalix BioTherapeutics’ drug Elelyso – for the treatment of Type 1 Gaucher disease. The rare genetic disorder occurs in people who do not produce enough of an enzyme called glucocerebrosidase, resulting in liver or spleen damage, anemia, low blood platelet counts and bone problems. The drug is an injection that replaces the missing enzyme in patients with a confirmed diagnosis of Type 1 (non-neuropathic). Following the approval, Protalix will receive a $25 million milestone payment from Pfizer, which developed the treatment with the Israeli company.

  • NoCamels Team 7:34 am on April 21, 2012 Permalink | Reply
    Tags: drug, , Inter-Lab, ,   

    Merck Serono Opens Drug Development Incubator In Israel 

    Merck Serono -News Flash - IsraelMerck Serono, a division of German pharmaceutical giant Merck, is opening a drug development incubator in Yavne, Israel. The company will invest 10 million euros in the project, supporting the development of Israeli biotech companies. The project is led by Inter-Lab, the R&D center of Merck Serono in Israel, which has already selected a few projects from over 100 applications it received.


  • NoCamels Team 5:47 am on April 11, 2012 Permalink | Reply
    Tags: , drug, Lauren Sciences, parkinson, V-Smart   

    ‘BGN Technologies’ Licenses Drug Delivery Platform To NY Firm 

    BGN - News Flash - IsraelBGN Technologies, the technology transfer company for Ben-Gurion University of the Negev (BGU), has signed a licensing agreement for its V-Smart drug delivery technology with Lauren Sciences LLC, a privately held biotechnology company in New York. Lauren Sciences will develop the technology as a platform for treating a variety of diseases that affect the central nervous system, including Parkinson’s, Alzheimer’s and Amyotrophic Lateral Sclerosis (ALS). The V-Smart technology pinpoints where the drug will be released in the brain, to increase efficacy and reduce adverse effects.

  • NoCamels Team 3:15 pm on April 10, 2012 Permalink | Reply
    Tags: Can-Fite, drug, eye inflammation, preclinical trial, uvea   

    ‘Can-Fite’ Announces Positive Results In Eye Inflammation Drug Trial 

    CanFite - News Flash - IsraelIsraeli biopharmaceutical company Can-Fite BioPharma announced successful results in the preclinical trial of CF101 – a drug for the treatment of inflammations of the uvea, which is the middle layer of the eye. Such inflammations can result in blindness and according to the company are the fifth or sixth leading causes of blindness in the US.

Compose new post
Next post/Next comment
Previous post/Previous comment
Show/Hide comments
Go to top
Go to login
Show/Hide help
shift + esc